An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)

Roche

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01332981

ML22958

Details and patient eligibility

About

This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.

Enrollment: 220 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patient, >/= 18 years of age
• Metastatic breast cancer
• 1st-line treatment with Herceptin initiated in 2002
• Included in pharmaco-epidemiologic HERMINE study

Exclusion criteria

• Patient died before scheduled follow-up visit (March 2005)

Trial design

220 participants in 1 patient group

Cohort